Mechanism of action of mRNA-based vaccines

References

• Pollard C, De Koker S, Saelens X, et al. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013;19(12):705–713.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468.
   PubMed Web of Science ®Google Scholar
• Weissman D. mRNa transcript therapy. Expert Vacc Rev. 2015;14(2):265–281.
   Google Scholar
• Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365):152–154.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745–1749.
   PubMed Web of Science ®Google Scholar
• Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. 1993;23(7):1719–1722.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184(2):465–472.
   PubMed Web of Science ®Google Scholar
• Hovav AH, Panas MW, Rahman S, et al. Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes. J Immunol. 2007;179(10):6725–6733.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol. 2016;41:18–22.
   PubMed Web of Science ®Google Scholar
• DeFrancesco L. The ‘anti-hype’ vaccine. Nat Biotechnol. 2017;35(3):193–197.
   PubMed Web of Science ®Google Scholar
• Ljungberg K, Liljestrom P. Self-replicating alphavirus RNA vaccines. Expert Rev Vaccines. 2015;14(2):177–194.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Alphavirus-based vaccines. Viruses. 2014;6(6):2392–2415.
   PubMed Web of Science ®Google Scholar
• Kramps T, Elbers K. Introduction to RNA vaccines. Methods Mol Biol. 2017;1499:1–11.
   PubMedGoogle Scholar
• Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109(36):14604–14609.
   PubMed Web of Science ®Google Scholar
• Fros JJ, Pijlman GP. Alphavirus infection: host cell shut-off and inhibition of antiviral responses. Viruses. 2016;8(6):166.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine. 2009;28(2):484–493.
   PubMed Web of Science ®Google Scholar
• Brito LA, Chan M, Shaw CA, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther. 2014;22(12):2118–2129.
   PubMed Web of Science ®Google Scholar
• Kübler H, Scheel B, Gnad-Vogt U, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. 2015;3:26.
   PubMed Web of Science ®Google Scholar
• Sebastian M, Papachristofilou A, Weiss C, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 2014;14:748.
   PubMed Web of Science ®Google Scholar
• Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012;30(12):1210–1216.
   PubMed Web of Science ®Google Scholar
• Knudsen ML, Ljungberg K, Kakoulidou M, et al. Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. J Virol. 2014;88(21):12438–12451.
   PubMed Web of Science ®Google Scholar
• Chahal JS, Khan OF, Cooper CL, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci U S A. 2016;113(29):E4133–4142.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248–251.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;169(1):176.
   PubMed Web of Science ®Google Scholar
• Magini D, Giovani C, Mangiavacchi S, et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS One. 2016;11(8):e0161193.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401.
   PubMed Web of Science ®Google Scholar
• Avogadri F, Merghoub T, Maughan MF, Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One. 2010;5(9):e12670.
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines. Hum Vaccin Immunother. 2013;9(10):2263–2276.
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med. 2012;14(6):428–439.
   PubMed Web of Science ®Google Scholar
• Wen Y, Monroe J, Linton C, et al. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine. 2014;32(30):3796–3804.
   PubMed Web of Science ®Google Scholar
• Seregin SS, Appledorn DM, McBride AJ, et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther. 2009;17(4):685–696.
   PubMed Web of Science ®Google Scholar
• Pyankov OV, Bodnev SA, Pyankova OG, et al. A Kunjin replicon virus-like particle vaccine provides protection against Ebola virus infection in nonhuman primates. J Infect Dis. 2015;212 Suppl 2:S368–S371.
   PubMed Web of Science ®Google Scholar
• Bogers WM, Oostermeijer H, Mooij P, et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis. 2015;211(6):947–955.
   PubMed Web of Science ®Google Scholar
• Brazzoli M, Magini D, Bonci A, et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol. 2015;90(1):332–344.
   PubMed Web of Science ®Google Scholar
• Schnee M, Vogel AB, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl Trop Dis. 2016;10(6):e0004746.
   PubMed Web of Science ®Google Scholar
• Vormehr M, Schrors B, Boegel S, et al. Mutanome engineered RNA immunotherapy: towards patient-centered tumor vaccination. J Immunol Res. 2015;595363:2015.
   Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1–15.
   PubMed Web of Science ®Google Scholar
• Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31(2):180–188.
   PubMed Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009;32(5):498–507.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19(5):990–999.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology. 2016;5(5):e1108511.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316–1327.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343–353.
   PubMed Web of Science ®Google Scholar
• Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 2007;14(15):1175–1180.
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Doener F, Zanzinger K, et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016;34(33):3882–3893.
   PubMed Web of Science ®Google Scholar
• Lazzaro S, Giovani C, Mangiavacchi S, et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology. 2015;146(2):312–326.
   PubMed Web of Science ®Google Scholar
• Pepini T, Pulichino AM, Carsillo T, et al. Induction of an interferon-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. Unpublished manuscript submitted for publication. 2017;198(10):4012–4024.
   Google Scholar
• Edwards DK, Jasny E, Yoon H, et al. Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med. 2017;15(1):1.
   PubMed Web of Science ®Google Scholar
• Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol. 1996;157(9):4159–4165.
   PubMed Web of Science ®Google Scholar
• van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, et al. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med. 2005;201(8):1281–1292.
   PubMed Web of Science ®Google Scholar
• Duewell P, Kisser U, Heckelsmiller K, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol. 2011;187(1):55–63.
   PubMed Web of Science ®Google Scholar
• Iavarone C, Ramsauer K, Kubarenko AV, et al. A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol. 2011;186(7):4213–4222.
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Jego G. Toll-like receptors–sentries in the B-cell response. Immunology. 2009;128(3):311–323.
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529–1531.
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303(5663):1526–1529.
   PubMed Web of Science ®Google Scholar
• Scheel B, Braedel S, Probst J, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol. 2004;34(2):537–547.
   PubMed Web of Science ®Google Scholar
• Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10(2):103–106.
   PubMed Web of Science ®Google Scholar
• Pollard C, Rejman J, De Haes W. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251–259.
   PubMed Web of Science ®Google Scholar
• Kanasty RL, Whitehead KA, Vegas AJ, et al. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3):513–524.
   PubMed Web of Science ®Google Scholar
• Lonez C, Vandenbranden M, Ruysschaert JM. Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev. 2012;64(15):1749–1758.
   PubMed Web of Science ®Google Scholar
• Heidenreich R, Jasny E, Kowalczyk A, et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer. 2015;137(2):372–384.
   PubMed Web of Science ®Google Scholar
• De Beuckelaer A, Grooten J, De Koker S. Type I interferons modulate CD8+ T cell immunity to mRNA vaccines. Trends Mol Med. 2017;23(3):216–226.
   PubMed Web of Science ®Google Scholar
• Broos K, Van der Jeught K, Puttemans J, et al. Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon. Mol Ther Nucleic Acids. 2016;5:e326.
   PubMedGoogle Scholar
• Cruz CC, Suthar MS, Montgomery SA, et al. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology. 2010;399(1):1–10.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Shaw CA, Otten GR, et al. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity. Virology. 2013;447(1–2):254–264.
   PubMed Web of Science ®Google Scholar
• De Beuckelaer A, Pollard C, Van Lint S, et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol Ther. 2016;24(11):2012–2020.
   Web of Science ®Google Scholar
• Sheehan KC, Lai KS, Dunn GP, et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res. 2006;26(11):804–819.
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–545.
   PubMed Web of Science ®Google Scholar
• Simmons JD, White LJ, Morrison TE, et al. Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff. J Virol. 2009;83(20):10571–10581.
   PubMed Web of Science ®Google Scholar
• Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319–1330.
   PubMed Web of Science ®Google Scholar
• Youn H, Chung JK. Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther. 2015;15(9):1337–1348.
   PubMed Web of Science ®Google Scholar
• Kim DY, Atasheva S, McAuley AJ, et al. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs. Proc Natl Acad Sci USA. 2014;111(29):10708–10713.
   Google Scholar
• Ziemniak M, Strenkowska M, Kowalska J, et al. Potential therapeutic applications of RNA cap analogs. Future Med Chem. 2013;5(10):1141–1172.
   PubMed Web of Science ®Google Scholar
• Kuhn AN, Diken M, Kreiter S, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 2010;17(8):961–971.
   PubMed Web of Science ®Google Scholar
• Kolupaeva VG, Pestova TV, Hellen CU. Ribosomal binding to the internal ribosomal entry site of classical swine fever virus. Rna. 2000;6(12):1791–1807.
   PubMed Web of Science ®Google Scholar
• McCullough KC, Milona P, Thomann-Harwood L, et al. Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. Vaccines (Basel). 2014;2(4):735–754.
   PubMedGoogle Scholar
• Jia J, Yao P, Arif A, et al. Regulation and dysregulation of 3ʹUTR-mediated translational control. Curr Opin Genet Dev. 2013;23(1):29–34.
   PubMed Web of Science ®Google Scholar
• Hyde JL, Chen R, Trobaugh DW, et al. The 5ʹ and 3ʹ ends of alphavirus RNAs–non-coding is not non-functional. Virus Res. 2015;206:99–107.
   PubMed Web of Science ®Google Scholar
• Hyde JL, Gardner CL, Kimura T, et al. A viral RNA structural element alters host recognition of nonself RNA. Science. 2014;343(6172):783–787.
   PubMed Web of Science ®Google Scholar
• Bell CL, Yu D, Smolke CD, et al. Control of alphavirus-based gene expression using engineered riboswitches. Virology. 2015;483:302–311.
   PubMed Web of Science ®Google Scholar
• Zhong F, Cao W, Chan E, et al. Deviation from major codons in the Toll-like receptor genes is associated with low Toll-like receptor expression. Immunology. 2005;114(1):83–93.
   PubMed Web of Science ®Google Scholar
• Ricci EP, Kucukural A, Cenik C, et al. Staufen1 senses overall transcript secondary structure to regulate translation. Nat Struct Mol Biol. 2014;21(1):26–35.
   PubMed Web of Science ®Google Scholar
• Carpenter S, Ricci EP, Mercier BC, et al. Post-transcriptional regulation of gene expression in innate immunity. Nat Rev Immunol. 2014;14(6):361–376.
   PubMed Web of Science ®Google Scholar
• Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol Biol. 2017;1499:109–121.
   PubMedGoogle Scholar
• Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175.
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
   PubMed Web of Science ®Google Scholar
• Probst J, Brechtel S, Scheel B, et al. Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther. 2006;4:4.
   PubMedGoogle Scholar
• Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000;30(1):1–7.
   PubMed Web of Science ®Google Scholar
• Moon JJ, Huang B, Irvine DJ. Engineering nano- and microparticles to tune immunity. Adv Mater. 2012;24(28):3724–3746.
   PubMed Web of Science ®Google Scholar
• Thoryk EA, Swaminathan G, Meschino S, et al. Co-administration of lipid nanoparticles and sub-unit vaccine antigens is required for increase in antigen-specific immune responses in mice. Vaccines (Basel). 2016;4(4). pii: E47.
   PubMed Web of Science ®Google Scholar
• Sahin U, Kariko K, Tureci O. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780.
   PubMed Web of Science ®Google Scholar
• Su X, Fricke J, Kavanagh DG, et al. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm. 2011;8(3):774–787.
   PubMed Web of Science ®Google Scholar
• Neuberg P, Kichler A. Recent developments in nucleic acid delivery with polyethylenimines. Adv Genet. 2014;88:263–288.
   PubMed Web of Science ®Google Scholar
• Wang WX, Dai K, Hong L, et al. The strategies of endosomal escape for intracellular gene delivery. Yao Xue Xue Bao. 2014;49(8):1111–1116.
   PubMedGoogle Scholar
• Mockey M, Bourseau E, Chandrashekhar V, et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007;14(9):802–814.
   PubMed Web of Science ®Google Scholar
• Bedoui S, Whitney PG, Waithman J, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009;10(5):488–495.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Heirman C, Thielemans K, et al. mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother. 2013;9(2):265–274.
   PubMed Web of Science ®Google Scholar
• Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol. 2000;7(3):168–173.
   PubMed Web of Science ®Google Scholar
• Jefford M, Schnurr M, Toy T, et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood. 2003;102(5):1753–1763.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Renmans D, Broos K, et al. The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines. 2015;14(2):235–251.
   PubMed Web of Science ®Google Scholar
• Senti G, Kundig TM. Intralymphatic immunotherapy. World Allergy Organ J. 2015;8(1):9.
   PubMed Web of Science ®Google Scholar
• Martinez-Gomez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150(1):59–65.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908–17912.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–9040.
   PubMed Web of Science ®Google Scholar
• Diken M, Kreiter S, Selmi A, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011;18(7):702–708.
   PubMed Web of Science ®Google Scholar
• Selmi A, Vascotto F, Kautz-Neu K, et al. Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunol Immunother. 2016;65(9):1075–1083.
   PubMed Web of Science ®Google Scholar
• Lorenz C, Fotin-Mleczek M, Roth G, et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 2011;8(4):627–636.
   PubMed Web of Science ®Google Scholar
• Scheel B, Aulwurm S, Probst J, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol. 2006;36(10):2807–2816.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16(6):1170–1180.
   PubMed Web of Science ®Google Scholar
• Michiels A, Tuyaerts S, Bonehill A, et al. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. Methods Mol Biol. 2008;423:155–163.
   PubMedGoogle Scholar
• Van Lint S, Renmans D, Broos K, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. 2016;4(2):146–156.
   PubMed Web of Science ®Google Scholar
• Kim SS, Peng LF, Lin W, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007;132(1):311–320.
   PubMed Web of Science ®Google Scholar
• Ishimoto S, Kawamoto K, Stover T, et al. A glucocorticoid reduces adverse effects of adenovirus vectors in the cochlea. Audiol Neurootol. 2003;8(2):70–79.
   PubMed Web of Science ®Google Scholar